MYELOPROLIFERATIVE NEOPLASMS TREATMENT MARKET ANALYSIS

Myeloproliferative Neoplasms Treatment Market, By Disease Type (Essential Thrombocythemia (ET), Myelofibrosis (MF), Polycythemia Vera (PV)), By Drug Class (Tyrosine Kinase Inhibitors, Janus kinase inhibitors (JAKi), Antimetabolites, Others (alkylating agents, etc.)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Nov 2023
Code : CMI930
Pages :180
Formats :
Excel and PDF
Industry : Pharmaceutical

Myeloproliferative Neoplasms Treatment MarketSize and Trends

The Global Myeloproliferative Neoplasms Treatment Market is estimated to be valued at US$ 9.4 Billion in 2023 and is expected to exhibit a CAGR of 3.9% during the forecast period (2023-2030).

Global Myeloproliferative Neoplasms Treatment Market – Drivers

Increasing research and development activities by the market players: Increasing research and development activities by the market players is expected to prople the market growth over the forecast period. For instance, in May 4, 2023, PharmaEssentia, a pharmaceutical company, announced the initiation of its ECLIPSE PV Phase IIIb clinical trial of ropeginterferon alfa-2b-njft (BESREMi) for the treatment of polycythemia vera (PV), a rare, chronic and life-threatening blood cancer. The single-arm study will evaluate an accelerated dosing schedule for ropeginterferon alfa-2b-njft against the currently labelled dosing in 100 adults from U.S. and Canada. Moreover, the subjects will receive starting dosage of 250mcg, 350mcg at week two, with a target optimal dose of 500mcg at week four. In September 8, 2022, Silence Therapeutics, a pharmaceutical company, was granted fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of polycythemia vera.